Zenas BioPharma, Inc.
ZBIO
Positions held
Your positionsZBIO isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Zenas BioPharma operates in the biotechnology sector, which is known for its potential to innovate and create groundbreaking therapies, positioning the company for future growth as it develops its pipeline.
- The company's market cap stands at approximately $1.76 billion, indicating a significant valuation in the biotech space.
- ZBIO has a strong buy recommendation, suggesting investor confidence in its future performance.
- ZBIO has a high debt-to-equity ratio of 120.54, indicating potential financial risk and reliance on debt financing.
- The company reported a net income loss of $111.456 million in Q2 2026, reflecting ongoing financial challenges.
- ZBIO's score indicates a strong sell signal with a score of -16.00, highlighting negative market sentiment and performance trends.
Fundamentals
| Market cap | $1.71B | Enterprise value | $1.36B | Trailing P/E | — | Forward P/E | -5.63 |
| PEG | — | Price / book | 6.72 | Beta | -0.88 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | -77.7% |
| Profit margin | 0.0% | ROE | -2.0% | ROA | -34.4% | Debt / equity | 1.21 |
| Current ratio | 9.93 | Free cash flow | -$211.39M | Analyst recommendation | strong_buy | Mean target | $47.88 |
| 52w high | $44.60 | 52w low | $13.50 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $1.0M | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | -7765.9% | — | — | — | — | — |
| Net income | -$111M | -$81.0M | -$240M | -$51.5M | -$52.2M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$77.7M | -$77.3M | -$71.3M | -$47.6M | -$55.2M | — |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $10.0M | $5.0M | $50.0M | $0.0M |
| Op margin | -2113.8% | -3277.8% | -54.3% | — |
| Net income | -$378M | -$157M | -$37.1M | -$119M |
| Gross margin | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | -$211M | -$164M | -$27.1M | -$75.2M |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-06 · Zenas BioPharma to Host Virtual R&D Event
2026-09-30 · Zenas BioPharma's Obexelimab Faces Larger IgG4-RD Opportunity, Wedbush Says
2026-09-23 · Can Zenas BioPharma’s (ZBIO) Clinical Pipeline Justify Its Heavy Cash Burn?
2026-09-23 · Why Is Zenas BioPharma (ZBIO) Filing More Than $240 Million In Shelves?
2026-09-18 · Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-09-08 · Zenas BioPharma to Host Obexelimab IgG4-RD Investor Event
2026-09-04 · Zenas BioPharma to Present at Upcoming Healthcare Investor Conferences
2026-08-28 · Fortune Brands and 4 More Stocks See Action From Activist Investors
2026-08-18 · Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-08-13 · Zenas BioPharma's Q2 Net Loss Widens; CFO to Step Down
Price (daily)
Full chart · RSI · MACD · patterns